Salus Scientific

About Salus Scientific

Salus Scientific is a medical technology company founded in 2021 that develops solutions to improve occupational safety for healthcare workers in fluoroscopy-guided environments. The company was co-founded by Dr. William P. Buchanan, a practicing interventional cardiologist, and Todd O. Flohr, who serves as CEO. Dr. Buchanan's personal experience with chronic pain from a work-related injury inspired the creation of the company's first product, designed to alleviate the physical strain caused by heavy lead aprons worn during medical procedures. The company's flagship product is the GLiFT™, a patented endoskeleton system that redistributes the weight of lead aprons away from the neck, shoulders, and back to the user's pelvis. This design aims to reduce fatigue and long-term musculoskeletal strain for clinicians who must wear radiation protection for extended periods. The GLiFT™ system features rigid "mantis bars" to shift the load, an adjustable belt with memory foam, and is available in various configurations, including front and side-entry aprons. In addition to the GLiFT™, Salus Scientific's portfolio includes the Salus Shield™, a managed service program for healthcare facilities to streamline the management of personal radiation protection equipment (PRPE). This service offers digital inventory tracking, inspection and compliance documentation, and access to other Salus technologies. The company also offers smart wearable solutions for real-time radiation exposure tracking, including a personal dosimeter and the RadApp mobile application. Other products include AeroShield™, PeRM™, and various accessories like thyroid shields and sleeves. Headquartered in Mount Pleasant, South Carolina, Salus Scientific operates on a business model that includes direct sales of its products to hospitals and clinics, alongside its managed services. The company targets healthcare professionals who perform fluoroscopy-guided procedures, such as interventional cardiologists, technologists, and nurses. In August 2026, Salus Scientific closed an oversubscribed Series A funding round, raising $10.1 million to support its commercial scale-up, expand production, and develop its clinical infrastructure.